A Phase III Study of JNS020QD in Cancer Pain Patients - Evaluation of the Efficacy and Safety of JNS020QD Switched From Opioid Analgesics
Phase of Trial: Phase III
Latest Information Update: 07 May 2013
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 29 Jan 2009 Actual patient numbers (70) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2008 Planned end date (Jun 2008) added as reported by ClinicalTrials.gov.